X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-20 | BTAI | Bioxcel Therapeutics, Inc. | Yocca Frank | Chief Scientific Officer | S - Sale+OE | $1.09 | -6,845 | 26,175 | -21% | -$7,427 | |||||
| D | 2026-05-20 | BTAI | Bioxcel Therapeutics, Inc. | Rodriguez Javier | See Remarks | S - Sale+OE | $1.08 | -6,560 | 26,803 | -20% | -$7,111 | |||||
| D | 2026-05-20 | BTAI | Bioxcel Therapeutics, Inc. | Steinhart Richard I | CFO | S - Sale+OE | $1.09 | -6,845 | 26,300 | -21% | -$7,427 | |||||
| D | 2026-05-20 | BTAI | Bioxcel Therapeutics, Inc. | Mehta Vimal | CEO, Pres | S - Sale+OE | $1.09 | -19,419 | 550,066 | -3% | -$21,108 | |||||
| D | 2026-05-22 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $30.27 | -200,000 | 1,613,063 | -11% | -$6,054,000 | |||||
| DM | 2026-05-20 | GYRE | Gyre Therapeutics, Inc. | Ye Weiguo | COO | S - Sale+OE | $6.15 | -22,220 | 700,000 | -3% | -$136,653 | |||||
2026-05-22 | MDGL | Madrigal Pharmaceuticals, Inc. | Levy Richard S | Dir | S - Sale | $515.44 | -5,682 | 22,015 | -21% | -$2,928,716 | ||||||
2026-05-22 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.46 | -6,500 | 77,565 | -8% | -$35,463 | ||||||
| D | 2026-05-21 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $564.11 | -10,000 | 18,876 | -35% | -$5,641,130 | |||||
2026-05-19 | SER | Serina Therapeutics, Inc. | Marshall Richard Peter | Dir | P - Purchase | $1.65 | +12,183 | 12,183 | New | +$20,102 | ||||||
| D | 2026-05-21 | ORKA | Oruka Therapeutics, Inc. | Dambkowski Carl | Dir | S - Sale+OE | $58.97 | -105,000 | 73,743 | -59% | -$6,191,366 | |||||
| D | 2026-05-21 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $564.11 | -9,500 | 679,797 | -1% | -$5,359,011 | |||||
2026-05-22 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $108.47 | -6,149 | 41,613 | -13% | -$666,982 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Reilly Joseph James | See Remarks | S - Sale | $6.27 | -3,719 | 149,836 | -2% | -$23,309 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Hohenleitner Susan | CFO | S - Sale | $6.27 | -1,455 | 229,078 | -1% | -$9,119 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Bishop John E | See Remarks | S - Sale | $6.27 | -2,306 | 336,845 | -1% | -$14,453 | ||||||
2026-05-21 | ARVN | Arvinas, Inc. | Teel Randy | Pres, CEO | S - Sale | $9.04 | -2,209 | 285,009 | -1% | -$19,962 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Brady James Parker | CHRO | S - Sale | $6.27 | -1,846 | 261,066 | -1% | -$11,570 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Foster Eric Duane | Chief Commercial Officer | S - Sale | $6.27 | -7,998 | 417,972 | -2% | -$50,127 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Kelliher Mike | Chief Business Officer | S - Sale | $6.27 | -7,248 | 357,418 | -2% | -$45,427 | ||||||
2026-05-20 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $17.12 | +2,500 | 18,000 | +16% | +$42,800 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale | $6.27 | -6,989 | 429,093 | -2% | -$43,804 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $6.27 | -54,748 | 1,745,397 | -3% | -$343,133 | ||||||
2026-05-20 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $64.43 | +1,563 | 505,000 | 0% | +$100,712 | ||||||
2026-05-20 | AZN | Astrazeneca Plc | Sharma Mani | See Remarks | S - Sale | $185.78 | -11,893 | 19,262 | -38% | -$2,209,482 | ||||||
| D | 2026-05-20 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $110.56 | -4,302 | 0 | -100% | -$475,631 | |||||
2026-05-21 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $11.00 | -10,000 | 173,614 | -5% | -$110,000 | ||||||
| D | 2026-05-20 | PHVS | Pharvaris N.V. | Bjork Elisabeth | Dir | S - Sale+OE | $29.32 | -10,000 | 15,167 | -40% | -$293,166 | |||||
2026-05-21 | NATR | Natures Sunshine Products Inc | Brower Nathan G | EVP, GC | S - Sale | $21.84 | -12,015 | 43,438 | -22% | -$262,408 | ||||||
2026-05-20 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $52.75 | -13,684 | 37,217 | -27% | -$721,838 | ||||||
2026-05-20 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $1.87 | +76,344 | 3,588,240 | +2% | +$142,779 | ||||||
| A | 2026-05-18 | AVIR | Atea Pharmaceuticals, Inc. | Murphy Polly A. | Dir | P - Purchase | $4.17 | +6,100 | 92,145 | +7% | +$25,446 | |||||
2026-05-19 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $65.51 | -199 | 20,975 | -1% | -$13,036 | ||||||
2026-05-19 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $65.51 | -444 | 75,073 | -1% | -$29,086 | ||||||
2026-05-19 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.54 | +468,551 | 800,000 | +141% | +$721,548 | ||||||
| D | 2026-05-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $565.98 | -9,500 | 679,797 | -1% | -$5,376,814 | |||||
| D | 2026-05-21 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $562.82 | -8,300 | 45,172 | -16% | -$4,671,399 | |||||
2026-05-20 | TRDA | Entrada Therapeutics, Inc. | Zeiher Bernhardt G | Dir | P - Purchase | $5.86 | +5,000 | 5,000 | New | +$29,316 | ||||||
| M | 2026-05-18 | ZOMDF | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.10 | +200,000 | 4,425,000 | +5% | +$20,600 | |||||
| M | 2026-05-20 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Sr. Vice President, Sales | P - Purchase | $0.11 | +216,899 | 6,001,000 | +4% | +$22,797 | |||||
2026-05-19 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.01 | -2,409 | 1,447,156 | 0% | -$7,261 | ||||||
2026-05-19 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.01 | -662 | 677,977 | 0% | -$1,995 | ||||||
2026-05-19 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.01 | -384 | 89,780 | 0% | -$1,157 | ||||||
2026-05-13 | ANL | Adlai Nortye Ltd. | Lu Yang | CEO, 10% | S - Sale | $13.18 | -10 | 99,990 | 0% | -$132 | ||||||
2026-05-19 | RNXT | Renovorx, Inc. | Voll Mark | CFO | P - Purchase | $0.79 | +25,000 | 239,580 | +12% | +$19,690 | ||||||
| M | 2026-05-18 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $58.91 | -75,000 | 2,307,198 | -3% | -$4,418,010 | |||||
2026-05-18 | CNSP | Cns Pharmaceuticals, Inc. | Charles Faith L. | Dir | P - Purchase | $4.79 | +7,100 | 7,100 | New | +$34,002 | ||||||
| D | 2026-05-18 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.55 | -417 | 63,443 | -1% | -$11,488 | |||||
| D | 2026-05-15 | PHVS | Pharvaris N.V. | Glassman Robert | Dir | S - Sale+OE | $29.82 | -10,000 | 10,500 | -49% | -$298,245 | |||||
2026-05-15 | PHVS | Pharvaris N.V. | Abele Stefan Andreas | Chief Technical Ops Officer | S - Sale | $29.82 | -8,748 | 35,194 | -20% | -$260,864 | ||||||
2026-05-15 | PHVS | Pharvaris N.V. | Souverijns Wim | Chief Commercial Officer | S - Sale | $29.92 | -10,000 | 45,111 | -18% | -$299,163 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $2.97 | +1,843 | 12,129 | +18% | +$5,474 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Pres Research, Development | P - Purchase | $2.97 | +1,545 | 17,761 | +10% | +$4,589 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $2.97 | +1,369 | 9,334 | +17% | +$4,066 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Chief Administrative Officer | P - Purchase | $2.97 | +1,583 | 8,344 | +23% | +$4,702 | ||||||
2026-05-15 | PCSA | Processa Pharmaceuticals, Inc. | Skibsted Russell | CFO | P - Purchase | $2.97 | +1,984 | 8,466 | +31% | +$5,892 | ||||||
| A | 2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $2.97 | +1,843 | 8,267 | +29% | +$5,474 | |||||
| D | 2026-05-15 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $72.18 | -2,812 | 105,212 | -3% | -$202,958 | |||||
| A | 2026-04-30 | PCSA | Processa Pharmaceuticals, Inc. | Bigora Sian | Chief Development Officer | P - Purchase | $2.71 | +1,971 | 7,748 | +34% | +$5,341 | |||||
| D | 2026-05-15 | ELAN | Elanco Animal Health Inc | Modi Rajeev A. | SEE REMARKS | P - Purchase | $20.35 | +4,911 | 160,812 | +3% | +$99,939 | |||||
| D | 2026-05-15 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Pres, CEO, Dir | P - Purchase | $20.09 | +4,971 | 2,223,869 | 0% | +$99,843 | |||||
| D | 2026-05-18 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $567.31 | -10,000 | 18,876 | -35% | -$5,673,098 | |||||
2026-05-18 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $65.08 | -13,651 | 359,194 | -4% | -$888,419 | ||||||
| D | 2026-05-15 | BBIO | Bridgebio Pharma, Inc. | Scott Randal W. | Dir | S - Sale+OE | $67.15 | -10,000 | 15,589 | -39% | -$671,456 | |||||
| DM | 2026-05-15 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $19.87 | -100,000 | 1,122,626 | -8% | -$1,986,875 | |||||
| D | 2026-05-15 | RYTM | Rhythm Pharmaceuticals, Inc. | German Christopher Paul | Corporate Controller, CAO | S - Sale+OE | $92.21 | -4,643 | 0 | -100% | -$428,131 | |||||
2026-05-15 | KROS | Keros Therapeutics, Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $10.58 | +1,000 | 9,450 | +12% | +$10,580 | ||||||
| D | 2026-05-15 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $18.76 | -3,000 | 3,622 | -45% | -$56,280 | |||||
| D | 2026-05-18 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $26.76 | -1,108 | 227,367 | 0% | -$29,650 | |||||
2026-05-15 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Dir | S - Sale | $43.49 | -3,250 | 52,250 | -6% | -$141,343 | ||||||
| D | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $7.53 | -79 | 7,954 | -1% | -$595 | |||||
| D | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $7.53 | -259 | 12,040 | -2% | -$1,950 | |||||
| D | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $7.53 | -77 | 7,838 | -1% | -$580 | |||||
| D | 2026-05-18 | MCRB | Seres Therapeutics, Inc. | Brady Kelly | See Remarks | S - Sale+OE | $7.53 | -59 | 8,562 | -1% | -$444 | |||||
2026-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bunnage Mark E. | EVP, Chief Scientific Officer | S - Sale | $453.45 | -33 | 7,284 | 0% | -$14,964 | ||||||
| D | 2026-05-18 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $26.76 | -1,032 | 143,934 | -1% | -$27,616 | |||||
2026-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $453.45 | -1,354 | 24,734 | -5% | -$613,971 | ||||||
| D | 2026-05-18 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $26.76 | -1,129 | 467,665 | 0% | -$30,212 | |||||
| D | 2026-05-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $6.28 | -41,666 | 1,800,145 | -2% | -$261,612 | |||||
| A | 2026-05-14 | KYNB | Kyntra Bio, Inc. | Wettig Thane | CEO | P - Purchase | $7.09 | +2,800 | 27,243 | +11% | +$19,852 | |||||
2026-05-15 | IMNM | Immunome Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $20.70 | +5,000 | 43,415 | +13% | +$103,500 | ||||||
2026-05-18 | HROW | Harrow, Inc. | Graves Adrienne L | Dir | P - Purchase | $31.07 | +1,000 | 1,000 | New | +$31,070 | ||||||
2026-05-18 | HROW | Harrow, Inc. | Silvernail Lauren P | Dir | P - Purchase | $31.00 | +1,000 | 1,000 | New | +$31,000 | ||||||
2026-05-18 | MPLT | Maplight Therapeutics, Inc. | Kroeger Christopher A. | CEO | S - Sale | $27.19 | -118,235 | 1,394,094 | -8% | -$3,215,000 | ||||||
2026-05-18 | ZBIO | Zenas Biopharma, Inc. | Moulder Leon O Jr | CEO | P - Purchase | $16.88 | +60,000 | 2,306,122 | +3% | +$1,012,800 | ||||||
| D | 2026-05-15 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $109.47 | -2,000 | 0 | -100% | -$218,940 | |||||
| D | 2026-05-18 | RARE | Ultragenyx Pharmaceutical Inc. | Suliman Shehnaaz | Dir | S - Sale+OE | $25.12 | -5,740 | 27,951 | -17% | -$144,189 | |||||
| D | 2026-05-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $568.11 | -9,500 | 679,797 | -1% | -$5,397,077 | |||||
| D | 2026-05-18 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $59.07 | -10,290 | 16,406 | -39% | -$607,806 | |||||
2026-05-18 | MDGL | Madrigal Pharmaceuticals, Inc. | Soergel David | Chief Medical Officer | S - Sale | $515.90 | -844 | 11,075 | -7% | -$435,420 | ||||||
2026-05-15 | ACIU | Ac Immune Sa | Pfeifer Andrea | CEO | S - Sale | $2.79 | -10,000 | 3,834,288 | 0% | -$27,935 | ||||||
| D | 2026-05-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $20.29 | -12,500 | 191,641 | -6% | -$253,649 | |||||
| D | 2026-05-15 | COLL | Collegium Pharmaceutical, Inc | Freund John Gordon | Dir | S - Sale+OE | $34.54 | -4,127 | 115,726 | -3% | -$142,547 | |||||
2026-05-14 | NBP | Novabridge Biosciences | Cao Sean Wuxiong | See Remarks | S - Sale | $1.99 | -21,399 | 35,073 | -38% | -$42,584 | ||||||
| D | 2026-05-14 | TEVA | Teva Pharmaceutical Industries Ltd | Lippman Evan | EVP, Business Development | S - Sale+OE | $35.58 | -41,658 | 44,191 | -49% | -$1,482,367 | |||||
| DM | 2026-05-14 | GYRE | Gyre Therapeutics, Inc. | Ye Weiguo | COO | S - Sale+OE | $6.79 | -28,680 | 700,000 | -4% | -$194,773 | |||||
2026-05-14 | TEVA | Teva Pharmaceutical Industries Ltd | Kalif Eliyahu Sharon | EVP, CFO | S - Sale | $35.61 | -153,251 | 172,184 | -47% | -$5,457,375 | ||||||
2026-05-15 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Pres, CEO | S - Sale | $4.29 | -8,257 | 660,574 | -1% | -$35,413 | ||||||
2026-05-14 | ABCL | Abcellera Biologics Inc. | Montalbano John S. | Dir | P - Purchase | $4.77 | +20,000 | 246,000 | +9% | +$95,400 | ||||||
2026-05-14 | KYNB | Kyntra Bio, Inc. | Wettig Thane | CEO | P - Purchase | $7.09 | +2,800 | 27,243 | +11% | +$19,852 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |